Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Renamezin Capsule (an oral adsorbent) lowers indoxyl sulfate levels in patient with chronic
renal failure.
120 patients with chronic renal failure(baseline serum creatinine:1.5-5.0mg/dl).
Renamezin is administered 6.0mg/day. The treatment period is 2 months. The change in serum
indoxyl sulfate will be evaluated.